Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

被引：0

作者：

Qiu, Yan ^{[1
]}

Qian, Chong-Sheng ^{[1
]}

Zhou, Hai-Xia ^{[1
]}

Xu, Ming-Zhu ^{[1
]}

Kang, Li-Qing ^{[2
]}

Sun, Ai-Ning ^{[1
]}

Wu, De-Pei ^{[1
]}

Yu, Lei ^{[2
]}

Xue, Shengli ^{[1
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

[2] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-164636

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10337 / 10338

页数：2

共 50 条

[1] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
Phely, Laurent
Hensen, Luca
Faul, Christoph
Ruff, Christer Alexander
Schneider, Dina
Bethge, Wolfgang Andreas
Lengerke, Claudia
JAMA ONCOLOGY, 2024, 10 (06) : 789 - 792
[2] CD19 Chimeric Antigen Receptor T Cell Therapy for the Treatment of B Cell Lineage Acute Lymphoblastic Leukemia
Chen, Runzhe
Song, Xiao-Tong
Chen, Baoan
DISCOVERY MEDICINE, 2015, 20 (110) : 185 - 190
[3] CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
Aiyun Jin
Jingjing Feng
Guoqing Wei
Wenjun Wu
Luxin Yang
Huijun Xu
Yanlei Zhang
Jiazhen Cui
Alex Hongsheng Chang
Yongxian Hu
He Huang
Bone Marrow Transplantation, 2020, 55 : 717 - 721
[4] CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
Jin, Aiyun
Feng, Jingjing
Wei, Guoqing
Wu, Wenjun
Yang, Luxin
Xu, Huijun
Zhang, Yanlei
Cui, Jiazhen
Chang, Alex Hongsheng
Hu, Yongxian
Huang, He
BONE MARROW TRANSPLANTATION, 2020, 55 (04) : 717 - 721
[5] A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
Yang, Junfang
Li, Jianqiang
Zhang, Xian
Lv, Fanyong
Guo, Xiaoling
Wang, Qinglong
Wang, Lin
Chen, Dandan
Zhou, Xiaosu
Ren, Jinhai
Lu, Peihua
BLOOD, 2018, 132
[6] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
Xu, Hao
Lv, Qiuxia
Huang, Liang
Cao, Wenyue
Wang, Jue
Meng, Fankai
Li, Chunrui
Zheng, Miao
Chen, Liting
Mu, Ketao
Cheng, Jiali
Zhu, Li
Zhou, Jianfeng
Zhang, Yicheng
Wang, Na
Cao, Yang
CYTOTHERAPY, 2023, 25 (02) : 185 - 191
[7] Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
Liang, Zuyu
Cui, Jiazhen
Chang, Alex Hongsheng
Yu, Jian
Hu, Yongxian
Huang, He
REGENERATIVE THERAPY, 2020, 15 : 281 - 284
[8] Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
Liu, Shuangyou
Deng, Biping
Yin, Zhichao
Lin, Yuehui
An, Lihong
Liu, Dan
Pan, Jing
Yu, Xinjian
Chen, Bingzhen
Wu, Tong
Chang, Alex H.
Tong, Chunrong
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (06) : 671 - 679
[9] CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas
Cao, Yang
Xiao, Yi
Wang, Na
Wang, Gaoxiang
Huang, Liang
Hong, Zhenya
Meng, Li
Zhou, Xiaoxi
Wang, Jue
Yang, Yang
Xu, Hao
Zhang, Shangkun
Xiao, Min
Chen, Liting
Zheng, Miao
Li, Chunrui
Mao, Xia
Gu, Chaojiang
Zhang, Tongcun
Zhang, Yicheng
Zhou, Jianfeng
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (11): : 910.e1 - 910.e11
[10] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
Wang, Yiyun
Yang, Yingying
Hong, Ruimin
Zhao, Houli
Wei, Guoqing
Wu, Wenjun
Xu, Huijun
Cui, Jiazhen
Zhang, Yanlei
Chang, Alex H.
Hu, Yongxian
Huang, He
BLOOD CANCER JOURNAL, 2020, 10 (10)

← 1 2 3 4 5 →